LivaNova PLC
Research LivaNova PLC (LIVN) on Bullrun: valuation model: 30.8% overvalued, market cap USD 4.56B, P/E 42.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLIVN
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal30.8% overvalued
- Market capUSD 4.56B
- P/E42.9
- Financial periodFY2025
- RevenueUSD 1.39B
- Revenue growth10.7%
- Net income-USD 242.50M
- Free cash flowUSD 173.29M
- Gross margin67.7%
Valuation Snapshot
Bullrun's latest valuation model marks LivaNova PLC as 30.8% overvalued; latest market cap is USD 4.56B; P/E is 42.9.
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation.
Frequently asked questions
Is LivaNova PLC overvalued or undervalued?
Bullrun's valuation model currently marks LivaNova PLC as 30.8% overvalued.
What is LivaNova PLC's market cap?
LivaNova PLC's market capitalization is USD 4.56B.
What is LivaNova PLC's P/E ratio?
LivaNova PLC's price-to-earnings (P/E) ratio is 42.9.
What does LivaNova PLC do?
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland,...